Literature DB >> 12918003

Speech and language therapy interventions for children with primary speech and language delay or disorder.

J Law1, Z Garrett, C Nye.   

Abstract

BACKGROUND: It is thought that approximately 6% of children have speech and language difficulties of which the majority will not have any other significant developmental difficulties. Whilst most children's difficulties resolve, children whose difficulties persist into primary school may have long-term problems concerning literacy, socialisation, behaviour and school attainment.
OBJECTIVES: To examine the effectiveness of speech and language interventions for children with primary speech and language delay/disorder. SEARCH STRATEGY: The following databases were searched: The Cochrane Controlled Trials Register (Cochrane Library, CENTRAL: 2002/3), CINAHL (1982 - July 2002), EMBASE (1980 - Sept Week 4 2002), ERIC (1965 - 2002), MEDLINE (1966 - Sept Week 3 2002), PsycINFO (1872 - 2002/10 Week 2), The National Research Register (2002/3). In addition to this references were taken from reviews of the literature and reference lists from articles. SELECTION CRITERIA: The review considered randomised controlled trials of speech and language therapy interventions for children or adolescents with primary speech and language delay/disorder. DATA COLLECTION AND ANALYSIS: Titles and abstracts were identified and assessed for relevance, before the full text version was obtained of all potentially relevant articles. The data were categorised depending on the nature of the control group and considered in terms of the effects of intervention on expressive and receptive phonology, syntax and vocabulary. The outcomes used in the analysis were dependent on the focus of the study with only the primary effects of therapy being considered in this review. MAIN
RESULTS: The results of twenty-five studies were used in the meta-analysis. The results suggest that speech and language therapy is effective for children with phonological (SMD=0.44, 95%CI: 0.01,0.86) or vocabulary difficulties (SMD=0.89, 95%CI: 0.21,1.56), but that there is less evidence that interventions are effective for children with receptive difficulties (SMD=-0.04, 95%CI: -0.64,0.56). Mixed findings were found concerning the effectiveness of expressive syntax interventions (n=233; SMD=1.02, 95%CI: 0.04-2.01). No significant differences were shown between clinician administered intervention and intervention implemented by trained parents, and studies did not show a difference between the effects of group and individual interventions (SMD=0.01, 95%CI: -0.26,1.17). The use of normal language peers in therapy was shown to have a positive effect on therapy outcome (SMD=2.29, 95%CI: 1.11,3.48). REVIEWER'S
CONCLUSIONS: The review shows that overall there is a positive effect of speech and language therapy interventions for children with expressive phonological and expressive vocabulary difficulties. The evidence for expressive syntax difficulties is more mixed, and there is a need for further research to investigate intervention for receptive language difficulties. There is a large degree of heterogeneity in the results, and the sources of this need to be investigated.

Entities:  

Mesh:

Year:  2003        PMID: 12918003     DOI: 10.1002/14651858.CD004110

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  58 in total

Review 1.  Screening in child health: studies of the efficacy and relevance of preventive care practices.

Authors:  Peter Weber; Oskar Jenni
Journal:  Dtsch Arztebl Int       Date:  2012-06-15       Impact factor: 5.594

2.  A Technology-Assisted Language Intervention for Children Who Are Deaf or Hard of Hearing: A Randomized Clinical Trial.

Authors:  Jareen Meinzen-Derr; Rose Sheldon; Mekibib Altaye; Laura Lane; Lindsay Mays; Susan Wiley
Journal:  Pediatrics       Date:  2021-01-15       Impact factor: 7.124

Review 3.  Psychological therapies for generalised anxiety disorder.

Authors:  V Hunot; R Churchill; M Silva de Lima; V Teixeira
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

4.  CDC Kerala 6: Validation of Language Evaluation Scale Trivandrum (0-3 y) against Receptive Expressive Emergent Language Scale in a developmental evaluation clinic population.

Authors:  M K C Nair; A O Mini; Deepa Bhaskaran; G S Harikumaran Nair; Babu George; M L Leena; Paul Swamidhas Sudhakar Russell
Journal:  Indian J Pediatr       Date:  2014-08-12       Impact factor: 1.967

5.  Psychodynamic therapies versus other psychological therapies for depression.

Authors:  Rachel Churchill; Theresa Hm Moore; Philippa Davies; Deborah Caldwell; Hannah Jones; Glyn Lewis; Vivien Hunot
Journal:  Cochrane Database Syst Rev       Date:  2010

6.  Psychodynamic therapies versus treatment as usual for depression.

Authors:  Theresa Hm Moore; Vivien Hunot; Philippa Davies; Deborah Caldwell; Hannah Jones; Glyn Lewis; Rachel Churchill
Journal:  Cochrane Database Syst Rev       Date:  2010

7.  Humanistic therapies versus other psychological therapies for depression.

Authors:  Rachel Churchill; Philippa Davies; Deborah Caldwell; Theresa Hm Moore; Hannah Jones; Glyn Lewis; Vivien Hunot
Journal:  Cochrane Database Syst Rev       Date:  2010

Review 8.  Specific language impairment: a convenient label for whom?

Authors:  Sheena Reilly; Bruce Tomblin; James Law; Cristina McKean; Fiona K Mensah; Angela Morgan; Sharon Goldfeld; Jan M Nicholson; Melissa Wake
Journal:  Int J Lang Commun Disord       Date:  2014 Jul-Aug       Impact factor: 3.020

9.  Interpersonal, cognitive analytic and other integrative therapies versus other psychological therapies for depression.

Authors:  Vivien Hunot; Theresa Hm Moore; Deborah Caldwell; Philippa Davies; Hannah Jones; Glyn Lewis; Rachel Churchill
Journal:  Cochrane Database Syst Rev       Date:  2010

10.  Humanistic therapies versus treatment as usual for depression.

Authors:  Philippa Davies; Vivien Hunot; Theresa Hm Moore; Deborah Caldwell; Hannah Jones; Glyn Lewis; Rachel Churchill
Journal:  Cochrane Database Syst Rev       Date:  2010
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.